The article also details potential side effects, consumer satisfaction, and comparisons with other GLP-1 providers, helping readers make informed decisions about their weight loss treatment path
The FDA approved Rybelsus, an oral version of semaglutide manufactured by the drug company Novo Nordisk, in 2019
This is not a replacement for trials, but it can move much faster, and that speed matters when a drug goes from niche to mainstream almost overnight. A major challenge in this process, which Guntuku calls computational social listening, has been scale
First, for many GLP-1 users, its more than just staying hydratedits about comfort and well-being
Semaglutide also increased the risk of gallbladder-related disorders, particularly cholelithiasis, by over 2.5 times